试验数据-话题@MedSci

#试验数据#

60篇内容 | 1728人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2148503, encodeId=7f2a214850314, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=临床试验数据管理之数据记录的常见问题, objectType=article, longId=12997, objectId=75611299e75, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=75611299e75, replyNumber=0, likeNumber=67, createdTime=2023-07-17, rootId=0, userName=ms3000001527664206, userId=d7068788473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=吉林省, moduleDTOList=[ModuleDTO(moduleId=75611299e75, moduleTitle=临床试验数据管理之数据记录的常见问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75611299e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055272, encodeId=95df20552e24b, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=ERS上呈报的CONVERT临床试验数据显示，AeriSeal系统治疗晚期慢性阻塞性肺病/肺气肿患者取得初步成功, objectType=article, longId=738376, objectId=40a5e38376df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40a5e38376df, replyNumber=0, likeNumber=153, createdTime=2022-12-06, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40a5e38376df, moduleTitle=ERS上呈报的CONVERT临床试验数据显示，AeriSeal系统治疗晚期慢性阻塞性肺病/肺气肿患者取得初步成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40a5e38376df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055270, encodeId=65f920552e0d1, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=90, createdTime=2022-08-05, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055271, encodeId=c1ac20552e1d1, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=全球首个口服小分子PD-(L)1人体试验数据披露, objectType=article, longId=220327, objectId=c2c022032e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2c022032e75, replyNumber=0, likeNumber=84, createdTime=2022-03-28, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2c022032e75, moduleTitle=全球首个口服小分子PD-(L)1人体试验数据披露, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2c022032e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055269, encodeId=99d9205526915, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=台湾高端疫苗公布二期试验数据，第二剂后28天的血清阳转率达99.8%？, objectType=article, longId=212594, objectId=a7562125942e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7562125942e, replyNumber=0, likeNumber=86, createdTime=2021-11-30, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7562125942e, moduleTitle=台湾高端疫苗公布二期试验数据，第二剂后28天的血清阳转率达99.8%？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7562125942e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055268, encodeId=03e020552685c, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, objectType=article, longId=209884, objectId=8e3c20988469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3c20988469, replyNumber=0, likeNumber=86, createdTime=2021-06-12, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3c20988469, moduleTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3c20988469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055267, encodeId=4c0c205526e86, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=使用体外诊断试剂境外临床试验数据的技术指南（征求意见稿）, objectType=article, longId=203790, objectId=13f5203e904e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13f5203e904e, replyNumber=0, likeNumber=116, createdTime=2021-04-23, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13f5203e904e, moduleTitle=使用体外诊断试剂境外临床试验数据的技术指南（征求意见稿）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13f5203e904e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055266, encodeId=2cd5205526682, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, objectType=article, longId=194157, objectId=c3b319415e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3b319415e0d, replyNumber=0, likeNumber=77, createdTime=2020-07-25, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3b319415e0d, moduleTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3b319415e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055265, encodeId=e6172055265a8, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=总缓解率达100% ，金斯瑞子公司传奇生物公布CAR-T美国临床试验数据, objectType=article, longId=184481, objectId=a42e1844818f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a42e1844818f, replyNumber=0, likeNumber=85, createdTime=2020-05-31, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a42e1844818f, moduleTitle=总缓解率达100% ，金斯瑞子公司传奇生物公布CAR-T美国临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a42e1844818f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055263, encodeId=7f0a20552636c, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=BTK抑制剂ARQ 531的I期试验数据, objectType=article, longId=168606, objectId=a3671686067b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3671686067b, replyNumber=0, likeNumber=92, createdTime=2019-08-06, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3671686067b, moduleTitle=BTK抑制剂ARQ 531的I期试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3671686067b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055264, encodeId=3fba2055264f9, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=又一批药物将接受临床试验数据核查, objectType=article, longId=181359, objectId=e33a1813598f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e33a1813598f, replyNumber=0, likeNumber=84, createdTime=2020-02-19, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e33a1813598f, moduleTitle=又一批药物将接受临床试验数据核查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e33a1813598f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055259, encodeId=882b205525971, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=ASH 2018：创新药临床试验数据汇总, objectType=article, longId=155232, objectId=e9cf15523250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9cf15523250, replyNumber=0, likeNumber=74, createdTime=2019-10-07, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9cf15523250, moduleTitle=ASH 2018：创新药临床试验数据汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9cf15523250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055261, encodeId=c973205526199, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=2019年ASCO泌尿生殖系统癌症研讨会：TIVO-3试验数据, objectType=article, longId=160424, objectId=ea31160424fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea31160424fe, replyNumber=0, likeNumber=75, createdTime=2019-09-03, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea31160424fe, moduleTitle=2019年ASCO泌尿生殖系统癌症研讨会：TIVO-3试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea31160424fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055260, encodeId=dd532055260fb, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=日本干细胞疗法上市引争议：仅13人受试，未公开试验数据, objectType=article, longId=160065, objectId=ec97160065c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec97160065c4, replyNumber=0, likeNumber=87, createdTime=2019-11-26, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec97160065c4, moduleTitle=日本干细胞疗法上市引争议：仅13人受试，未公开试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec97160065c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055257, encodeId=b707205525e82, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=药物临床试验数据核查持续发力, objectType=article, longId=146182, objectId=239214618269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=239214618269, replyNumber=0, likeNumber=79, createdTime=2019-04-02, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=239214618269, moduleTitle=药物临床试验数据核查持续发力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=239214618269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055262, encodeId=a7ed205526227, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布, objectType=article, longId=162523, objectId=00a21625233c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a21625233c, replyNumber=0, likeNumber=61, createdTime=2019-07-28, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a21625233c, moduleTitle=Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a21625233c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055255, encodeId=19632055255e3, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=80, createdTime=2018-08-28, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055258, encodeId=ca202055258bb, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=PreCar肝癌早筛项目先导试验数据已全球领先, objectType=article, longId=150725, objectId=002f150e252b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=002f150e252b, replyNumber=0, likeNumber=90, createdTime=2019-04-12, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=002f150e252b, moduleTitle=PreCar肝癌早筛项目先导试验数据已全球领先, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=002f150e252b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055256, encodeId=31f52055256e2, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=《接受药品境外临床试验数据的技术指导原则》正式发布, objectType=article, longId=143474, objectId=7bd11434e47a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bd11434e47a, replyNumber=0, likeNumber=94, createdTime=2018-11-16, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bd11434e47a, moduleTitle=《接受药品境外临床试验数据的技术指导原则》正式发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bd11434e47a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055252, encodeId=8f7e20552523a, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, objectTitle=药品审评审批信息公开办法征求意见：等效性试验数据应公开, objectType=article, longId=127056, objectId=321012e056d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=321012e056d3, replyNumber=0, likeNumber=99, createdTime=2018-04-06, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=321012e056d3, moduleTitle=药品审评审批信息公开办法征求意见：等效性试验数据应公开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=321012e056d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

试验数据

2020-05-29

ms3000001527664206 (审核中...)

前往app查看评论内容

#试验数据#

临床试验数据管理之数据记录的常见问题

2023-07-17发表于吉林省

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

ERS上呈报的CONVERT临床试验数据显示，AeriSeal系统治疗晚期慢性阻塞性肺病/肺气肿患者取得初步成功

2022-12-06

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2022-08-05

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

全球首个口服小分子PD-(L)1人体试验数据披露

2022-03-28

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

台湾高端疫苗公布二期试验数据，第二剂后28天的血清阳转率达99.8%？

2021-11-30

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性

2021-06-12

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

使用体外诊断试剂境外临床试验数据的技术指南（征求意见稿）

2021-04-23

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存

2020-07-25

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

总缓解率达100% ，金斯瑞子公司传奇生物公布CAR-T美国临床试验数据

2020-05-31

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

BTK抑制剂ARQ 531的I期试验数据

2019-08-06

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

又一批药物将接受临床试验数据核查

2020-02-19

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

ASH 2018：创新药临床试验数据汇总

2019-10-07

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

2019年ASCO泌尿生殖系统癌症研讨会：TIVO-3试验数据

2019-09-03

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

日本干细胞疗法上市引争议：仅13人受试，未公开试验数据

2019-11-26

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

药物临床试验数据核查持续发力

2019-04-02

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布

2019-07-28

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2018-08-28

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

PreCar肝癌早筛项目先导试验数据已全球领先

2019-04-12

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

《接受药品境外临床试验数据的技术指导原则》正式发布

2018-11-16

ms24272190615788285182 (审核中...)

前往app查看评论内容

#试验数据#

药品审评审批信息公开办法征求意见：等效性试验数据应公开

2018-04-06

科室
- - 订阅+
  - 更多科室
工具
服务